1. Home
  2. Services
  3. Vaccine Development
  4. Post-Vaccination Immune Response

Post-Vaccination Immune Response

Understanding Post-Vaccination Immune Responses

After vaccination, the immune system undergoes a complex adaptive process, transitioning from innate immunity to later-stage adaptive responses. Advanced immuno-monitoring technologies, particularly Protein Biochip platforms, provide high-dimensional, multi-parameter data to thoroughly analyze these responses. The core value of these technologies lies in identifying protective immune biomarkers and enabling research teams to pinpoint predictive immune response characteristics.

Monitoring immune responses post-vaccination is a critical step in vaccine development. Especially in the face of global pandemics, rapidly and accurately assessing vaccine-induced responses is essential to protect public health.

During the development of COVID-19 vaccines, post-vaccination immune monitoring helped scientists identify early immune biomarkers, offering crucial data for designing effective vaccines. With Protein Biochip technology, it's possible to track real-time immune responses such as cytokine release and antibody production, enabling early predictions of vaccine efficacy and individual immune responsiveness.

Figure 1. Intensity plot for the top peptides selected by peptide microarray, grouped by time point. (Source: Valentini D, et al. 2017)Figure 1. Intensity plot for the top peptides selected by peptide microarray, grouped by time point. (Source: Valentini D, et al. 2017)

Evaluating Influenza Vaccines? SARS-CoV-2 Vaccines? We've Got You Covered!

Creative Diagnostics' Protein Biochip technology is tailored for immuno-monitoring and response evaluation during vaccine development:

High Sensitivity with Multi-Target Detection

Equipped with advanced laser confocal imaging and fluorescence labeling techniques, our platform simultaneously detects multiple immune markers, including cytokines, antibodies, and immune cell markers. This provides comprehensive data on post-vaccination immune responses, aiding in the identification of potential immune escape mechanisms or low-responder populations.

Systems Biology and Data Integration

Our platform supports deep data integration and bioinformatics analysis, utilizing tools like t-SNE, PCA, and UMAP for dimensionality reduction. For instance, in yellow fever (YF-17D) and influenza vaccine studies, researchers identified early immune biomarkers linked to long-term protection, accelerating vaccine optimization.

Predict and Optimize Immune Responses

With precise data analysis, we offer early predictions of immune responses, identifying factors that influence their intensity and duration. For example, studies have shown a strong correlation between antigen-specific responses and early biomarkers (e.g., CXCL10 levels) post-SARS-CoV-2 vaccination. Our Protein Biochip technology helps you identify these indicators to optimize vaccine design and dosing strategies.

Customized Services

We offer flexible, tailored services, including screening and analysis of specific immune biomarkers and personalized evaluations of vaccine immune responses. This is especially beneficial for clients optimizing vaccines for different populations or formulations.

Array Example

PanelExample CombinationTarget ApplicationPossible Sample Preparation
Panel A
(Humoral)		IgG1, IgG2a/c, IgG2b, IgG3, IgM, IgA (+ antigen-specific arrays)1. Quantify vaccine-induced antibody levels (isotype/subclass)
2. Detect possible allergic (IgE) or mucosal (IgA) components		- In vitro: B cell culture supernatants if evaluating isotype switching
- In vivo: Serum/plasma at multiple timepoints post-immunization (e.g., days 7, 14, 21)
Panel B
(Cytokines)		IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17A, TNF-α, TGF-β, MCP-11. Profile Th bias (Th1 vs. Th2 vs. Th17) and regulatory signals
2. Identify pro-inflammatory cytokine surges (safety)		- In vitro: Cell culture supernatants (PBMCs or splenocytes restimulated with vaccine antigen)
- In vivo: Serum, or ex vivo restimulation of lymph node/spleen cells followed by supernatant analysis
Panel C
(Cellular Markers)		CD4, CD8, CD25, CD69, PD-1, CD44, CD62L, CD127, B cell lineage markers (e.g., CD19/CD27 in humans)1. Evaluate T cell activation/exhaustion post-vaccination
2. Monitor effector vs. memory cell development		- In vitro: Flow-based arrays or cell-based multiplex platforms measuring surface markers on restimulated T cells
- In vivo: Tissue digests (spleen, LN) or PBMC samples for cell surface analysis, if supported by array/flow-based detection

Why Choose Creative Diagnostics?

  • Efficient, Comprehensive Analysis with Minimal Sample Volume: Perfect for clients with scarce samples or tight timelines, our platform delivers high-quality data without compromising efficiency.
  • Automated Data Analysis Tools: Our integrated tools extract critical biomarkers from complex datasets, boosting interpretation accuracy, enhancing predictive capabilities, and minimizing manual errors.
  • Broad Application Across Vaccine Types: Our Protein Biochip technology is applicable not only to conventional vaccines like influenza or SARS-CoV-2 but also to therapeutic vaccines such as cancer and tuberculosis vaccines. We support enhanced vaccine safety and immunogenicity for diverse research needs.

With Creative Diagnostics' Protein Biochip technology, your vaccine development team can obtain precise, comprehensive immune response data in record time.

Searching for tools to support early vaccine evaluation and optimization? Unsure how to ensure your vaccine's efficacy and safety? Contact us today!

Reference

  1. Valentini D, Rao M, Rane L, et al. Peptide microarray-based characterization of antibody responses to host proteins after bacille Calmette–Guérin vaccination. Int J Infect Dis. 2017;56:140-154.
Online Inquiry
Services